Portola Pharmaceuticals to Announce Third Quarter 2019 Financial Results on Tuesday, November 5, 201 | PTLA Message Board Posts

Portola Pharmaceuticals, Inc.

  PTLA website

PTLA   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  6516 of 6590  at  10/15/2019 2:02:23 PM  by

seanleecfa


Portola Pharmaceuticals to Announce Third Quarter 2019 Financial Results on Tuesday, November 5, 2019

Anyone calling for $40m+ this quarter? I'm looking forward to earnings day next month, expecting $35m but if momentum is real, we can see $40m+ next month. 
 
 
Portola Pharmaceuticals to Announce Third Quarter 2019 Financial Results on Tuesday, November 5, 2019

SOUTH SAN FRANCISCO, Calif., Oct. 15, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) today announced that it will host a webcast and conference call to discuss the Company's financial results for the quarter ended September 30, 2019, and provide a general business overview, on Tuesday, November 5, 2019, at 4:30 p.m. ET (1:30 p.m. PT).

Conference Call Details
The live conference call on Tuesday, November 5, 2019, at 4:30 p.m. ET, can be accessed by phone by calling (844) 452-6828 from the United States and Canada or 1 (765) 507-2588 internationally and using the passcode 2980632. The webcast can be accessed live on the Investor Relations section of the Company's website at http://investors.portola.com. It will be archived for 30 days following the call.

About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals is a global, commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics that could significantly advance the fields of thrombosis and other hematologic conditions. The Company's first two commercialized products are Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo], marketed in Europe as Ondexxya® (andexanet alfa), and Bevyxxa® (betrixaban). The company also is advancing cerdulatinib, a SYK/JAK inhibitor being developed for the treatment of hematologic cancers. Founded in 2003 in South San Francisco, California, Portola has operations in the United States and Europe.

SOURCE Portola Pharmaceuticals, Inc.®

For further information: Investor Contact: Jennifer Zibuda, Portola Pharmaceuticals, IR@portola.com; Media Contact: Pure Communications, Portola_Media@purecommunications.com
 


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 3     Views: 308
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
6517 Re: Portola Pharmaceuticals to Announce Third Quarter 2019 Financial Results on Tuesday, November 5, 2019 MarkD 2 10/15/2019 3:32:08 PM


About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...